QCC-374 (QCC 374; QCC374) is a novel, potent and first-in-class prostanoid agonist with the potential to be used for the treatment of PAH-pulmonary arterial hypertension. QCC374 is an inhaled compound formulated for dry powder inhalation and is a selective agonist for the prostacyclin receptor. Because QCC374 is designed for inhalation, it is expected to have improved safety, tolerability and ease of use compared to other similar drugs.

纯度：≥98%

CAS：1356331-63-9